Common Deficiencies in Biologics Applications in Singapore – What Applicants Should Watch Out For

Biologics submissions are often more complex than small molecule applications, not just due to the science but because of the higher regulatory scrutiny involved. In Singapore, HSA’s review of biologics focuses heavily on product quality, clinical safety, and manufacturing consistency.

At TRC, we’ve supported multiple clients preparing or refining their Common Technical Document (CTD) dossiers for biologic products. Here are some of the most common issues we’ve encountered — either flagged during internal quality checks or in regulatory feedback from HSA:

1. Incomplete Viral Safety Data

Biologics derived from cell lines or involving human/animal raw materials must include robust viral clearance studies and testing for adventitious agents. Missing or insufficient viral validation summaries can delay review significantly. Applicants should ensure that viral reduction steps are well justified and validated.

2. Gaps in Comparability Data

When there are changes in manufacturing processes, comparability studies are essential to show that the pre- and post-change product remains equivalent in quality and efficacy. This is a frequent sticking point, especially for companies with foreign data relying on prior regulatory approvals. HSA expects a clear and data-driven comparability package — not just a reference to EMA or FDA acceptance.

3. Inadequate Characterization of Cell Banks

Master Cell Bank (MCB) and Working Cell Bank (WCB) characterization should be detailed and compliant with ICH Q5D/Q5B. Some applicants overlook genetic stability data or omit full sterility and purity test reports — items that HSA considers critical.

4. Lack of Clear Endotoxin and Sterility Validation

For injectable biologics, sterility and endotoxin testing methods must be fully validated and described in Module 3. In some cases, clients assume that referencing a compendial method is enough — but validation under actual product conditions (matrix effect, interference) must still be demonstrated.

5. Container Closure Integrity Not Adequately Demonstrated

Especially for prefilled syringes or vials, HSA may request evidence of container closure integrity (CCI) testing, particularly under worst-case shipping or storage conditions. CCI studies should be product-specific and reflect real-world usage, not just generic studies.

Biologics submissions are resource-intensive — but a strong CTD package reduces review time and prevents unnecessary back-and-forth with the authority. At TRC, we support clients in spotting and addressing these issues early, so they don’t become stumbling blocks down the road.

If your team is preparing a biologics application for the Singapore market and would like a second pair of eyes on your dossier, feel free to reach out.

Back To Blog